Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Symmans

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Breast Cancer Research and Treatment|June 3, 2018
Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancerJay P Reddy, Rachel L Atkinson, Richard Larson, et al.
Breast Cancer Research : BCR|June 23, 2025
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trialRoberto A Leon-Ferre, K Dimitroff, C Yau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineCatherine Van Poznak, Mark R Somerfield, Robert C Bast, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2014
Influence of biospecimen variables on proteomic biomarkers in breast cancerFunda Meric-Bernstam, Argun Akcakanat, Huiqin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimenAman U Buzdar, Vicente Valero, Nuhad K Ibrahim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2023
Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell CarcinomaAbdullah A Osman, Emre Arslan, Mason Bartels, et al.
Breast Cancer (Tokyo, Japan)|June 13, 2024
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational statusMelinda L Telli, Jennifer K Litton, J Thaddeus Beck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2015
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaborationV Bossuyt, E Provenzano, W F Symmans, et al.
Endocrine-Related Cancer|December 3, 2005
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeedingW F Symmans, D J Fiterman, S K Anderson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2024
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trialL A Huppert, D Wolf, C Yau, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|June 3, 2018
Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancerJay P Reddy, Rachel L Atkinson, Richard Larson, et al.
Breast Cancer Research : BCR|June 23, 2025
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trialRoberto A Leon-Ferre, K Dimitroff, C Yau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineCatherine Van Poznak, Mark R Somerfield, Robert C Bast, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2014
Influence of biospecimen variables on proteomic biomarkers in breast cancerFunda Meric-Bernstam, Argun Akcakanat, Huiqin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimenAman U Buzdar, Vicente Valero, Nuhad K Ibrahim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2023
Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell CarcinomaAbdullah A Osman, Emre Arslan, Mason Bartels, et al.
Breast Cancer (Tokyo, Japan)|June 13, 2024
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational statusMelinda L Telli, Jennifer K Litton, J Thaddeus Beck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2015
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaborationV Bossuyt, E Provenzano, W F Symmans, et al.
Endocrine-Related Cancer|December 3, 2005
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeedingW F Symmans, D J Fiterman, S K Anderson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2024
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trialL A Huppert, D Wolf, C Yau, et al.
Pageof 10